Scientific presentation selector

Prolonged Elranatamab Treatment Interruption in Patients with RRMM in the MagnetisMM-3 Study

Lesokhin AM, Niesvizky R, Arnulf B, Larson SM, Strouse C, Fernandez de Larrea C, Vesole DH, Nagai Y, Sullivan S, Leip E, Viqueira A, Bahlis N

Impact de l’arrêt prolongé du traitement par elranatamab chez des patients atteints de myélome multiple en rechute ou réfractaire (MMRR) : analyse rétrospective issue de l’essai MagnetisMM-3

Bertrand Arnulf, Alexander M. Lesokhin, Ruben Niesvizky, Sarah M. Larson, Christopher Strouse, Carlos Fernandez de Larrea, David H. Vesole, Yuya Nagai, Sharon T. Sullivan, Eric Leip, Nizar J. Bahlis

Safety and Efficacy of Elranatamab + Nirogacestat in Patients With Relapsed or Refractory Multiple Myeloma: Results From the Phase 1b MagnetisMM-4 Study

Landgren O, Trudel S, Rosenblatt J, McCurdy A, Madan S, Ali SA, Bahlis NJ, Gabayan E, Vescio R, O’Gorman M, Cheng S, Jiang S, Hoyle M, Cheng J, Vandendries ER, Raje N

Quantitative clinical pharmacology analysis to support the dose escalation of elranatamab + nirogacestat in the MagnetisMM-4 study

Jiang S et. al

A Clinical Overview of Infections in Patients Receiving Elranatamab in Combination With Daratumumab and Lenalidomide for Newly Diagnosed Multiple Myeloma in the MagnetisMM-6 Trial

Byun JM. et al.

Elranatamab Fixed Dosing: The Optimal Dosing Strategy for Safety, Efficacy, and Convenience Across Body Weights

Mohamed Elmeliegy, Pooneh Soltantabar, Jennifer Hibma, Olivia Ashman, Hoi-Kei Lon

EFFICACY AND SAFETY OF LESS FREQUENT DOSING WITH ELRANATAMAB (ELRA) IN PATIENTS WITH RELAPSED ORREFRACTORY MULTIPLE MYELOMA (RRMM): A US SUBGROUP ANALYSIS FROM MAGNETISMM-3

Ajay Nooka, Christopher Strouse, Sarah M. Larson, Alexander Lesokhin, Asya Varshavsky-Yanovsky, David Vesole, Guenther Koehne, Elpitha Soussou, Sharon T. Sullivan, Eric Leip, Noopur Raje

The Effect of Switching to Less Frequent Dosing on Patient-reported Outcomes Among Patients With Relapsed/refractory Multiple Myeloma Treated With Elranatamab

Nizar Jacques Bahlis, Ajay K. Nooka, Marco DiBonaventura, Sharon T. Sullivan, Mohammad Ashraf Chaudhary, Mohamad Mohty

Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1

Hang Quach, Luděk Pour, Sebastian Grosicki, Hanlon Sia4, Jiri Minarik, Ja Min Byun, Cyrille Touzeau, Carmine Liberatore, Sharon T. Sullivan, Eric Leip, Eeman Shaikh, Andrea Viqueira, Meletios-Athanasios Dimopoulos

Efficacy and safety of less frequent dosing with elranatamab (ELRA) in patients with relapsed or refractory multiple myeloma (RRMM): a US subgroup analysis from MagnetisMM-3

Ajay Nooka, Christopher Strouse, Sarah Larson, Alexander Lesokhin, Asya Varshavsky-Yanovsky, David Vesole, Guenther Koehne, Elpitha Soussou, Sharon T. Sullivan, Eric Leip, Noopur Raje

MagnetisMM-32: a phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38–directed therapy

Girnius S, Kaedbey R, Ochoa P, Pour L, Le Calloch R, Slordahl T, De Becker A, Hong F, Hoyle M, Yver A, Finn G, Schuster S

The Direct and Indirect Economic Costs Associated with Providing Care for a Patient with Multiple Myeloma in the United States and Europe

Annunziata K, Sternbach N, Tanaka H, DiBonaventura M, Cappelleri J, Watkins J, Hughes D, Meche A, Kim CH, Kennedy CT, Scheurer H, LeBlanc TW

Efficacy of Elranatamab in Combination With Carfilzomib and Dexamethasone in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael H Tomasson, Eli Gabayan, Syed Ali, Gabriel Afram, Sona Ghorashi, Trish Creel, Luisa Paccagnella, Carolyn Lou, Ola Landgren

MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

H. Miles Prince, Nizar J. Bahlis , Paula Rodriguez-Otero, Lionel Karlin, Luke Akard, Asya Varshavsky-Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin

MagnetisMM-9: Efficacy and Safety of Step-Up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Mohamad Mohty, Nizar Jacques Bahlis, Ajay K. Nooka, Marco DiBonaventura, Joseph C. Cappelleri, Umberto Conte

An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano J. Costa, Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Sarasa M.A. Johnson, Francis Vekeman, Patrick Hlavacek, Aster Meche, Paul Cislo, David Hughes, Guido Nador, Marco DiBonaventura

Role of quantitative systems pharmacology (QSP) in optimizing elranatamab dosing regimen for relapsed/refractory multiple myeloma

Kamrine E. Poels, Mohamed Elmeliegy, Diane Wang, Jennifer Hibma, C.J. Musante, Blerta Shtylla

Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MagnetisMM-3

H. Miles Prince, Mohamad Mohty, Shinsuke Iida, Nizar J Bahlis, Sharon T Sullivan, Umberto Conte, Eric Leip, Andrea Viqueira, Alexander M. Lesokhin

LONG-TERM SURVIVAL AFTER ELRANATAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAGNETISMM-3

Mohty M, Iida S, Bahlis NJ, Sullivan ST, Conte U, Leip E, Viqueira A, Lesokhin AM

AN INDIRECT COMPARISON OF ELRANATAMAB’S PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FROM MAGNETISMM-3 VERSUS COUNTRY-SPECIFIC TREATMENT REGIMENS FROM REAL-WORLD DATA SOURCES

Luciano J. Costa, Benjamin Hebraud, Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Mikko Kosunen, Gabriel Afram, Lina Book, Helene Grand, Antoine Duckit8, Carole Mackosso, Esra Çakar, Roberto DiVirgilio, Barbara Veggia, Ryan Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Didem Aydin, Guido Nador, Marco DiBonaventura

A COMPARISON OF PATIENT-REPORTED PERIPHERAL NEUROPATHY AMONG PATIENTS TREATED WITH ELRANATAMAB VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

Paula Rodrίguez-Otero, Shinsuke Iida, Marc-Steffen Raab, Maria Victoria Mateos, Charis Charalampous, Shaji K. Kumar, Ricardo Parrondo, Saurabh Chhabra, Madhu Nagaraj, Mei Sheng Duh, Priyanka Bobbili, Aolin Wang, Jingyi Chen, Patrick Hlavacek, Jinma Ren, Guido Nador, Marco DiBonaventura, Erinn Goldman, David Hughes, Mohamad Mohty

UPDATED RESULTS OF A MATCHING-ADJUSTED INDIRECT COMPARISON OF ELRANATAMAB VERSUS TECLISTAMAB IN PATIENTS WITH TRIPLE-CLASS EXPOSED/REFRACTORY MULTIPLE MYELOMA

Isha Mol, Yannan Hu, Thomas W Leblanc, Joseph Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez Cruz, Patrick Hlavacek